HQ461

E3 Ligase: HQ461 is a research compound designed as a molecular glue that recruits the cereblon (CRBN) E3 ligase. This interaction stabilizes the ternary complex to enable selective ubiquitination of target proteins.

Target Protein: HQ461 primarily targets IKZF1 and IKZF3 transcription factors, which regulate lymphoid cell transcriptional programs. Binding facilitates their recognition and ubiquitination by CRBN.

Degradation Mechanism: HQ461 mediates proteasomal degradation via the ubiquitin–proteasome system. The CRBN–IKZF1/3 ternary complex promotes polyubiquitination, leading to recognition and clearance by the 26S proteasome.

• Molecular Glue Mechanism Exploration: HQ461 facilitates the study of molecular glue mechanisms by promoting the interaction between target proteins and E3 ubiquitin ligases, leading to selective protein degradation. This application is crucial for understanding the biochemical pathways and structural dynamics involved in targeted protein degradation.

• Targeted Degradation Pathway Analysis: Researchers can utilize HQ461 to dissect targeted degradation pathways, offering insights into the ubiquitin-proteasome system. The product aids in identifying key regulatory nodes and understanding how molecular glues can enhance or inhibit specific protein interactions, thus contributing to the development of novel therapeutic strategies.

• Protein-Protein Interaction Studies: HQ461 is instrumental in investigating protein-protein interactions within the cellular environment. By acting as a molecular glue, it stabilizes transient complexes, allowing for detailed analysis of interaction dynamics and the role of specific proteins in cellular processes, thereby advancing the field of chemical biology.

• Drug Discovery and Development: In the context of drug discovery, HQ461 serves as a prototype for designing new molecular glues. Its application in targeted protein degradation studies can lead to the identification of druggable targets, providing a foundation for developing next-generation therapeutics aimed at previously undruggable proteins.